Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound
From the combination of in-vitro and in-vivo results, Field Trip believes that the pharmacology and safety of FT-104 can be fully addressed using well-designed preclinical toxicology models.
- From the combination of in-vitro and in-vivo results, Field Trip believes that the pharmacology and safety of FT-104 can be fully addressed using well-designed preclinical toxicology models.
- Field Trip also announced that it has secured a Good Manufacturing Practices compliant (cGMP) contract manufacturer (CMO) for FT-104 manufacturing.
- The drug substance from the engineering batch will provide the quantities of FT-104 needed to complete formulation and preclinical development.
- About Field Trip Health Ltd.
Field Trip is a global leader in the development and delivery of psychedelic therapies.